PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Advanced Oncotherapy (AVO)

Advanced Oncotherapy

Total Voting Rights and Significant Shareholdings
RNS Number : 3945O
Advanced Oncotherapy PLC
29 January 2019
 

29 January 2019

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Total Voting Rights and Director and Significant Shareholdings

 

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, confirms that the 25,000,000 Subscription Shares issued pursuant to the Subscription announced on 21 December 2018 were admitted to trading on AIM ("Admission") on 28 January 2019.

 

The Company's issued share capital now consists of 194,566,092 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights is 194,566,092. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Directors' and Significant Shareholdings

Set out below are details of the Directors' beneficial shareholdings and, in so far as the Company has been made aware, shareholdings of certain new Significant shareholders following Admission, being DNCA Investments and Barrymore Investments Ltd.

 

Shareholder

Number of Shares

% of issued share capital

Liquid Harmony Limited

45,000,000

23.13%

DNCA Investments

12,000,000

6.17%

Barrymore Investments Ltd*

7,905,721

4.06%

Mr Michael S Bradfield (Non-executive Director)

7,080,740

3.64%

Dr Michael Sinclair & Family (Chairman)

6,594,660

3.39%

AB Segulah**

6,488,789

3.34%

Dr P N Plowman (Non-executive Director)

3,930,304

2.02%

Dr Enrico C Vanni (Non-executive Director)

1,926,361

0.99%

Mr Nicolas Serandour (Chief Executive Officer)

1,760,467

0.90%

Professor Stephen Myers (Non-executive Director)

783,902

0.40%

Mr Hans Van Celsing (Non-executive Director)

30,000

0.02%

 

*Barrymore Investments Ltd is a company under the control of Seamus Mulligan.

**Gabriel Urwitz (Non-executive Director) is a director of AB Segulah

 

Defined terms in this announcement shall have the same meaning as in the announcement of 21 December 2018 unless otherwise defined herein. 

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO




Stockdale Securities (Nomad & Joint Broker)


Antonio Bossi / David Coaten

Tel: +44 20 7601 6100



Stifel Nicolaus Europe (Joint Broker)


Jonathan Senior

Tel: +44 20 7710 7600



Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 54 1 893 / Mob: +44 7876 741 001

 

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TVREANFNADKNEEF
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close